PathoQuest to Participate in IABS 3rd NGS Meeting – Rockville, MD USA | 27-28 Sept. 2022
3rd IABS Conference on Next Generation Sequencing for Adventitious Virus Detection in Biologics for Humans and Animals | Co-Chaired by US FDA and EDQM
This meeting will focus on the recent expansion of scientific data and the current applications of next-generation sequencing technologies for adventitious virus detection in biological products.
This will include presentations on standardization and validation of the technical and bioinformatics steps involved in the NGS workflow and
applications of different NGS strategies for characterization and safety evaluation of biologics, including human and animal
vaccines, as well as gene therapy, and therapeutic products. Current regulatory expectations will be discussed.
The meeting will bring together representatives from industry, academia, contract research organizations, and international regulatory
bodies for developing a scientific consensus regarding recommendations for using NGS for the detection of adventitious viruses.
You can meet our speakers and the NGS specialists team at our booth or after the following talks:
Session 2 – Reference Materials, NGS Qualification and Validation | Tuesday, September 27, 2022, at 3:50 pm
Pascale Beurdeley, Ph.D. | Chief Scientific Officer at PathoQuestwill present RNA Next-generation Sequencing Transcriptomics Analysis: A Validated Method to Assess Viral Safety of Cell substrates
Session 3 – NGS Applications for Adventitious Virus Testing | Wednesday, September 28, 2022, at 8:30 am
Marc Eloit, DVM, Ph.D. – Founder and Scientific Advisor, PathoQuest | Head of “Pathogen Discovery Laboratory, Institut Pasteur will present Next Generation Sequencing Transcriptomics Analysis: An Alternative Method to Replace in Vivo Tests for Assessing the Viral Safety of Cells